Market Size of Rapid Plasma Reagin Test Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Rapid Plasma Reagin Test Market Analysis
The market for the rapid plasma reagin test is expected to exhibit a CAGR of 4.1% during the forecast period.
- The COVID-19 pandemic had a significant impact on market growth, as syphilis diagnoses decreased during the early stages of the pandemic. However, there was an increase in syphilis infections during the post-pandemic market scenario, which drove the demand for the rapid plasma reagin test. This rise in syphilis is expected to contribute to the growth of the market during the post-pandemic period.
- The rapid plasma reagin (RPR) test is a serological test used to screen for syphilis, a sexually transmitted infection caused by the spirochete bacterium Treponema pallidum. The market for the rapid plasma reagin test is being driven by an increasing prevalence of syphilis and increased awareness of sexually transmitted diseases.
- According to a report published by the World Health Organization (WHO) in July 2021, the global pooled prevalence of syphilis among homosexuals was 7.5%, and globally, there were an estimated 7 million new syphilis infections in 2021. The high rate of syphilis prevalence is expected to drive the demand for rapid plasma reagin tests, thereby contributing to the growth of the market. Additionally, the prevalence of syphilis infections among pregnant women is expected to drive the growth of the market owing to the growing demand for early diagnosis to obtain proper treatment.
- Several initiatives are being taken regarding STD diagnostics, further supporting the growth of the market over the forecast period. For instance, in December 2021, Clinton Health Access Initiative (CHAI), MedAccess, and SD Biosensor partnered to develop dual Syphilis rapid diagnostics tests for a cost under USD 1, which is recommended by the WHO. Such initiatives are augmenting the demand for rapid tests for the rapid plasma reagin test, which is expected to contribute to the growth of the market over the forecast period. However, the lack of adoption of disease screening in developing countries is expected to restrain the growth of the market over the forecast period.
Rapid Plasma Reagin Test Industry Segmentation
As per the scope of the report, the rapid plasma reagin (RPR) test is a serological test that is used to screen for syphilis, a sexually transmitted infection caused by the spirochete bacterium treponema pallidum.
The rapid plasma reagin test market is segmented by product type (rapid plasma reagin test kits, analyzers and instruments, and reagents), end user (hospitals, diagnostic laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Rapid Plasma Reagin Test Kits | |
| Analyzers and Instruments | |
| Reagents |
| By End-User | |
| Hospitals | |
| Diagnostic Laboratories | |
| Other End-Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Rapid Plasma Reagin Test Market Size Summary
The rapid plasma reagin test market is poised for growth, driven by the increasing prevalence of syphilis and heightened awareness of sexually transmitted infections. The market experienced a setback during the COVID-19 pandemic due to a decline in syphilis diagnoses, but has since rebounded with a rise in infections, particularly in the post-pandemic period. This resurgence is expected to fuel demand for the rapid plasma reagin test, a crucial serological tool for syphilis screening. The market is further supported by initiatives aimed at improving STD diagnostics, such as partnerships to develop cost-effective rapid diagnostic tests. However, challenges remain, particularly in developing regions where disease screening adoption is low, potentially hindering market expansion.
Regionally, North America is anticipated to lead the global market, bolstered by a rising incidence of sexually transmitted diseases and significant investments in research and development for early diagnosis and treatment. The United States and Canada are experiencing increased syphilis cases, which is driving demand for rapid plasma reagin tests. Similarly, Mexico is witnessing a rise in syphilis infections, contributing to market growth. The market is moderately fragmented, with key players like Cardinal Health Inc., Thermo Fisher Scientific, and Abbott Laboratories dominating. Technological advancements and the introduction of new products, such as MedMira's Reveal TP, are also expected to propel market growth, supported by robust healthcare infrastructure and high healthcare spending in these regions.
Rapid Plasma Reagin Test Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidence of Syphilis
-
1.2.2 Technological Advancement in Rapid Plasma Reagin Testing
-
1.2.3 Growing Awareness Regarding the Morbidity of Sexually Transmitted Diseases
-
-
1.3 Market Restraints
-
1.3.1 Lack of Adoption Regarding Disease Screening in Developing Countries
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product Type
-
2.1.1 Rapid Plasma Reagin Test Kits
-
2.1.2 Analyzers and Instruments
-
2.1.3 Reagents
-
-
2.2 By End-User
-
2.2.1 Hospitals
-
2.2.2 Diagnostic Laboratories
-
2.2.3 Other End-Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Rapid Plasma Reagin Test Market Size FAQs
What is the current Rapid Plasma Reagin Test Market size?
The Rapid Plasma Reagin Test Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Rapid Plasma Reagin Test Market?
Cardinal Health, Inc, Thermo Fisher Scientific, Abbott Laboratories (Alere), F. Hoffmann-La Roche Ltd and Bio-Rad Laboratories are the major companies operating in the Rapid Plasma Reagin Test Market.
